Dales Natalie 4

What Happened

• Natalie Dales, Chief of Research Operations and Portfolio Strategy at Odyssey Therapeutics, was granted a derivative award of 79,773 shares on 2026-05-07. The filing lists an acquisition price of $0.00, indicating a grant of options (not a cash purchase or immediate sale).
• The award vests in 48 equal monthly installments; the first installment is scheduled to vest on June 7, 2026, subject to Dales' continued service. The grant is a long-term compensation award rather than an immediate market purchase or disposition.

Key Details

• Transaction date: 2026-05-07; Form 4 filed: 2026-05-11 (timely).
• Transaction type: Grant / Award of a derivative security (option); reported acquisition amount: 79,773 shares at $0.00.
• Vesting: 48 equal monthly installments; first vesting on June 7, 2026 (per footnote).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote: Confirms the award is an option with the described monthly vesting schedule.
• No exercise price or immediate sale reported in the filing; this was not an exercise or cashless sale.

Context

• This is a compensation grant (option award). Such grants are common for employee incentives and do not reflect an immediate purchase or sale of stock. The options will only convert into owned shares if/when they vest and are exercised according to plan terms (exercise price, if any, not specified in the filing).